Down syndrome and the risk of severe RSV infection: A meta-Analysis

Pediatrics

Volumn 142, Issue 3, 2018, Pages

  Beckhaus, Andrea A ^a   Castro Rodriguez, Jose A ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ASSISTED VENTILATION; CHILDHOOD MORTALITY; DISEASE SEVERITY; DOWN SYNDROME; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORBIDITY; MORTALITY RISK; OXYGEN THERAPY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; ADOLESCENT; ARTIFICIAL VENTILATION; CHILD; COMPLICATION; INFANT; MORTALITY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HOSPITALIZATION; HUMANS; INFANT; INTENSIVE CARE UNITS; LENGTH OF STAY; OXYGEN INHALATION THERAPY; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 85052739029     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2018-0225     Document Type: Review

References (35)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-Analysis. Lancet. 2010;375(9725):1545-1555.
2. Bueno SM, Gonzalez PA, Riedel CA, Carreno LJ, Vasquez AE, Kalergis AM. Local cytokine response upon respiratory syncytial virus infection. Immunol Lett. 2011;136(2):122-129.
3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
4. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(suppl 4):S284-S289.
5. Watts R, Vyas H. An overview of respiratory problems in children with Down's syndrome. Arch Dis Child. 2013;98(10):812-817.
6. de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A. 2015;167A(4):756-767.
7. Tenenbaum A, Hanna RN, Averbuch D, Wexler ID, Chavkin M, Merrick J. Hospitalization of children with Down syndrome. Front Public Health. 2014;2:22.
8. Fitzgerald P, Leonard H, Pikora TJ, Bourke J, Hammond G. Hospital admissions in children with Down syndrome: Experience of a populationbased cohort followed from birth. PLoS One. 2013;8(8):e70401.
9. Dawson AL, Cassell CH, Oster ME, et al. Hospitalizations and associated costs in a population-based study of children with Down syndrome born in Florida. Birth Defects Res A Clin Mol Teratol. 2014;100(11):826-836.
10. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. 2011. Available at: Www.ohri.ca/programs/clinical-epidemiology/oxford.asp Accessed January 1, 2018 11.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ. 2003;327(7414):557-560.
12. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: A population-based retrospective study. BMC Pediatr. 2004;4(1):25.
13. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis-A prospective birthcohort study. Pediatrics. 2007;120(4). Available at: Www.pediatrics.org/cgi/content/full/120/4/e1076.
14. Medrano Lopez C, Garcia-Guereta Silva L, Lirio Casero J, Garcia Perez J; Grupo CIVIC, Grupo de Trabajo de Infecciones de la Sociedad Espanola de Cardiologia Pediatrica y Cardiopatias Congenitas. Respiratory infections, Down's syndrome and congenital heart disease: The CIVIC 21 study [in Spanish]. An Pediatr (Barc). 2009;71(1):38-46.
15. Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J. 2010;29(7):672-673.
16. Kristensen K, Hjuler T, Ravn H, Simoes EA, Stensballe LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: A populationbased cohort study. Clin Infect Dis. 2012;54(6):810-817.
17. Zachariah P, Ruttenber M, Simoes EA. Down syndrome and hospitalizations due to respiratory syncytial virus: A population-based study. J Pediatr. 2012;160(5):827-831.e1.
18. Zhang Q, Guo Z, Langley JM, Bai Z. Respiratory syncytial virus-Associated intensive care unit admission in children in Southern China. BMC Res Notes. 2013;6:447.
19. Stagliano DR, Nylund CM, Eide MB, Eberly MD. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr. 2015;166(3):703-709.e2.
20. Galleguillos C, Galleguillos B, Larios G, Menchaca G, Bont L, Castro-Rodriguez JA. Down's syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus. Acta Paediatr. 2016;105(11):e531-e535.
21. Lee YI, Peng CC, Chiu NC, Huang DT, Huang FY, Chi H. Risk factors associated with death in patients with severe respiratory syncytial virus infection. J Microbiol Immunol Infect. 2016;49(5):737-742.
22. Sanchez-Luna M, Medrano C, Lirio J; RISK-21 Study Group. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study. Influenza Other Respir Viruses. 2017;11(2):157-164.
23. Grut V, Soderstrom L, Naumburg E. National cohort study showed that infants with Down's syndrome faced a high risk of hospitalisation for the respiratory syncytial virus. Acta Paediatr. 2017;106(9):1519-1524.
24. Shi T, McAllister DA, O'Brien KL, et al; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet. 2017;390(10098):946-958.
25. Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing developments in RSV prophylaxis: A clinician's analysis. Curr Opin Virol. 2017;24:70-78.
26. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102 (3, pt 1):531-537.
27. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540.
28. Resch B, Pasnocht A, Gusenleitner W, Muller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005;50(5):397-403.
29. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J. 2004;23(suppl 1):S41-S45.
30. Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: Risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J. 2004;23(5):418-423.
31. American Academy of Pediatrics Committee on Infectious Diseases. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:609-618.
32. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection [published correction appears in Pediatrics. 2014;134(6):1221]. Pediatrics. 2014;134(2):415-420.
33. Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS. Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997-2012. PLoS One. 2016;11(4):e0152208.
34. Yi H, Lanctot KL, Bont L, et al; CARESS investigators. Respiratory syncytial virus prophylaxis in Down syndrome: A prospective cohort study. Pediatrics. 2014;133(6):1031-1037.
35. Kashiwagi T, Okada Y, Nomoto K. Palivizumab prophylaxis against respiratory syncytial virus infection in children with immunocompromised conditions or Down syndrome: A multicenter, post-marketing surveillance in Japan [published correction appears in Paediatr Drugs. 2018;20(3):291]. Paediatr Drugs. 2018;20(1):97-104.